GlassScriptPhysician profile
Deborah J Lipson
NPI 1902881816
$4,067.75
in general payments reported to CMS, 2019-2025
20 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $322 · 2021: $188 · 2022: $290 · 2023: $386 · 2024: $1,182 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,861.01 | 2019-2025 | Clareon, Rocklatan, Centurion |
| Abbvie INC. | $303.75 | 2022-2025 | |
| Glaukos Corporation | $288.79 | 2024-2025 | Idosetr, Idose |
| Novartis Pharmaceuticals Corporation | $239.53 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $219.81 | 2019-2024 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Oyster Point Pharma, INC. | $212.18 | 2024-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $179.67 | 2019-2025 | |
| Alimera Sciences, INC. | $150.07 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $116.89 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $103.41 | 2022-2025 | Dextenza |
| Harrow Eye, LLC | $93.85 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $52.47 | 2025 | Miebo |
| Rxsight INC | $47.92 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $40.61 | 2019-2020 | |
| Amgen INC. | $39.25 | 2024-2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $27.50 | 2022 | |
| Eyevance Pharmaceuticals LLC | $26.67 | 2022 | |
| Horizon Therapeutics Plc | $26.01 | 2023 | Tepezza |
| Sight Sciences, INC. | $23.73 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Lipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.